Primary malignant B-cell–type dural lymphoma: case report

Yamada, Shoko M.; Ikawa, Naoki; Toyonaga, Shinichi; Nakabayashi, Hiromichi; Park, Kae Chang; Shimizu, Katsuji

doi:10.1016/j.surneu.2006.02.033

Cited by 29 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(3,6) As opposed to most other types of PCNSLs, the course of primary malignant dural B-cell lymphomas is comparatively benign. As illustrated by Yamada et al (13) and Sanjeevi et al, (15) this particular subtype may be curable by surgical resection, with or without postoperative focal irradiation. However, it should be noted that, owing to the general lack of reported cases of primary malignant dural B-cell lymphoma, knowledge of this disease still remains limited.…”

Section: Discussionmentioning

confidence: 93%

“…(1,6) In Yamada et al's review of primary malignant dural lymphomas, the epidemiology showed female predominance, immunocompetency and longer survival rate among patients when compared to those with primary malignant intracerebral lymphomas. (13) However, there is a paucity of overall knowledge of its epidemiology, risk factors and behaviour.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An unusual presentation of primary malignant B-cell-type dural lymphoma

Low

Lai²,

Ng³

2014

smedj

View full text Add to dashboard Cite

Primary malignant B-cell-type dural lymphoma is a rare subtype of primary central nervous system lymphoma (PCNSL). We herein report an unusual case of diffuse B-cell lymphoma that presents as a chronic subdural haematoma without extracranial involvement. The notable aspects of this case include the patient's immunocompetence, a short clinical history of symptom onset, rapid neurological deterioration and a final diagnosis of high-grade PCNSL. This case highlights the challenges neurosurgeons face, especially in the emergency setting, when the disease manifests in varied presentations.Keywords: chronic subdural haematoma, primary central nervous system lymphoma, primary dural lymphoma Fig. 1 Pre-contrast axial CT image shows the patient's brain.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

An unusual presentation of primary malignant B-cell-type dural lymphoma

Low

Lai²,

Ng³

2014

smedj

View full text Add to dashboard Cite

show abstract

“…L'invasion des tissus mous de la calvaria est fréquente (figure 3) [5]. L'oedème péri tumoral dans les lymphomes méningés est plus important que dans les méningiomes [6].…”

Section: Discussion:-unclassified

Meningeal Lymphoma Revealed by Bilateral Exophthalmitis.

ghoth¹,

Mohamed²,

Nassar³

et al. 2018

IJAR

View full text Add to dashboard Cite

show abstract

“…The 5-year overall survival rate was greater than 86 % in MZLs (17). Diffuse large B-cell type lymphoma also has a relatively benign prognosis (21). In comparison, patients with non-Hodgkin lymphomas in the CNS have survived for 12 to 18 months (3), and only 8% have survived longer than 3 years (14).…”

Section: Discussionmentioning

confidence: 99%

A case of primary dural lymphoma : diffuse large b-cell type

Lee

Kim²,

Kim³

2014

Turkish Neurosurgery

View full text Add to dashboard Cite

Primary leptomeningeal lymphoma is very rare disease that is a subtype of primary central nervous system (CNS) lymphoma. Primary dural lymphoma is a subentity of primary leptomeningeal lymphoma and arises from the dura mater without systemic disease. A 47-year-old woman presented with an indolent mass in the right frontal region. The patient's physical examination demonstrated no focal neurological abnormality. Magnetic resonance imaging (MRI) study revealed a mass lesion in the right frontal region. The patient underwent a right frontal craniectomy and removal of tumor. Histological diagnosis was diffuse large B-cell lymphoma (DLBCL). The patient received chemotherapy with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (R-CHOP protocol) every 3 weeks for six cycles. The patient was discharged without neurological deficit and no evidence of tumor recurrence. There was no systemic dissemination of disease 72 months after the surgery. Until the optimal standard management protocol is established, the treatment should be with an individualized multidisciplinary approach and continued follow-up and clinical surveillance are recommended for every patient.

show abstract

Primary malignant B-cell–type dural lymphoma: case report

Cited by 29 publications

References 12 publications

An unusual presentation of primary malignant B-cell-type dural lymphoma

An unusual presentation of primary malignant B-cell-type dural lymphoma

Meningeal Lymphoma Revealed by Bilateral Exophthalmitis.

A case of primary dural lymphoma : diffuse large b-cell type

Contact Info

Product

Resources

About